Company code: Cansino Biologics Inc(688185) company abbreviation: Cansino Biologics Inc(688185) Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 Unprofitable and unprofitable when the company is listed □ yes √ no III. tips on major risks
The company has explained the risk factors that may have a significant adverse impact on the company in "IV. risk factors" of "section III Management Discussion and analysis" of this report. Please pay attention to the investment risk. 4、 All directors of the company attended the board meeting. 5、 Deloitte Touche Tohmatsu (special general partnership) has issued a standard unqualified audit report for the company. 6、 The person in charge of the company, Xuefeng Yu (Yu Xuefeng), the person in charge of accounting work, Luo Xi, and the person in charge of accounting organization (Accounting Supervisor), Li Lu, declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
According to the rules on share repurchases of listed companies and other relevant provisions, listed companies do not enjoy the right to profit distribution when repurchasing shares in the special account. According to the proposal of the board of directors, it is proposed to distribute a cash dividend of 8 yuan (including tax) for every 10 shares to all shareholders of the company. The company does not convert the capital reserve into share capital and does not give bonus shares. As of March 25, 2022, the total share capital of the company is 247449899 shares, and the total number of shares in the repurchase special securities account is 325000 shares. Based on this calculation, the total cash dividend to be distributed is 1976999920 yuan (including tax). If the distribution plan changes due to the listing of new shares, share repurchase and other matters during the period from the disclosure to the implementation of the distribution plan, the total amount of distribution will be adjusted based on the total share capital on the equity registration date of the future implementation of the distribution plan, and the specific adjustment will be announced separately. The profit distribution plan can be implemented only after being deliberated by the general meeting of shareholders of the company. 8、 Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable IX. risk statement of forward-looking statements √ applicable □ not applicable
The forward-looking statements such as future plans and development strategies involved in this report do not constitute the company's substantive commitment to investors. Please pay attention to investment risks. 10、 Is there any non operational occupation of funds by the controlling shareholders and their related parties? No
11、 Whether there is any external guarantee in violation of the specified decision-making procedures? No 12. Whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? No 13. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section 4 corporate governance Section V environment, social responsibility and other corporate governance Section VI important matters Section VII changes in shares and shareholders Section VIII preferred shares Section 9 corporate bonds 103 section x financial report one hundred and four
Financial statements containing the signatures of the company's legal representative, the person in charge of accounting and the person in charge of accounting and stamped with the catalogue seal of documents for future reference
The original of 2021 annual report signed by the legal representative of the company
Other relevant information
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
Cansino Biologics Inc(688185) , company refers to Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
The company and parent company
Cansino Biologics Inc(688185) Co., Ltd. refers to Tianjin Cansino Biologics Inc(688185) Biotechnology Co., Ltd., which is a limited liability company before the company is changed into a joint stock limited company
The group refers to Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company and its subsidiaries within the scope of consolidated financial statements
The controlling shareholder and actual refers to Xuefeng Yu (Yu Xuefeng), Zhu Tao, Dongxu Qiu (Qiu Dongxu), Helen Huihua and Mao (Mao Huihua), the controller
Wanbo biology refers to Tianjin Wanbo Biomedical Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Cansino Biologics Inc(688185) Canada refers to Canada Biology (Canada) Inc., a wholly-owned subsidiary of the company
Cansino Biologics Inc(688185) Singapore refers to cansino Biology (Singapore) Inc Pte.Ltd., a wholly-owned subsidiary of the company
Cansino Biologics Inc(688185) Hong Kong refers to Cansino Biologics Inc(688185) Biology (Hong Kong) Co., Ltd., which is a wholly-owned subsidiary of the company
Cansino Biologics Inc(688185) Shanghai refers to Cansino Biologics Inc(688185) Biology (Shanghai) Co., Ltd., which is a wholly-owned subsidiary of the company
Cansino Biologics Inc(688185) biotechnology refers to Cansino Biologics Inc(688185) (Shanghai) Biotechnology Co., Ltd., which is a subsidiary of Cansino Biologics Inc(688185) Shanghai control
Cansino Biologics Inc(688185) biological R & D refers to Cansino Biologics Inc(688185) (Shanghai) biological R & D Co., Ltd., which is a wholly-owned subsidiary of Cansino Biologics Inc(688185) Shanghai
Shangyao Cansino Biologics Inc(688185) refers to Shanghai Shangyao Cansino Biologics Inc(688185) biopharmaceutical Co., Ltd., which is a controlled subsidiary of the company
Three dimensional biotechnology refers to Shanghai three dimensional Biotechnology Co., Ltd
Industrial investment fund refers to Shanghai biomedical industry equity investment fund partnership (limited partnership)
Shanghai Pharmaceuticals Holding Co.Ltd(601607) refers to Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Tianjin Qianyi refers to Tianjin Qianyi enterprise management partnership (limited partnership), which is the shareholder and employee stock ownership platform of the company
Tianjin qianrui partnership and Tianjin qianrui Partnership Management Co., Ltd
Tianjin Qianzhi refers to Tianjin Qianzhi enterprise management partnership (limited partnership), which is the shareholder and employee stock ownership platform of the company
CSRC and China Securities Regulatory Commission
Supervisory Commission
Shanghai Stock Exchange and Shanghai Stock Exchange refer to Shanghai Stock Exchange
Yi Suo
Company Law refers to the company law of the people's Republic of China
Securities Law refers to the securities law of the people's Republic of China
The articles of association refers to the articles of association of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company in force of the company
The report period and this report refer to January December 2021
stage
Yuan, thousand yuan and ten thousand yuan refer to RMB yuan, thousand yuan, ten thousand yuan and one hundred million yuan
RMB100mn
Vaccine refers to the automatic immune preparation for preventing infectious diseases made of pathogenic microorganisms (such as bacteria, viruses, etc.) and their metabolites through artificial detoxification, inactivation or genetic engineering
Antigen refers to a kind of substance that can make people and animals produce immune response. It can not only stimulate the immune system to produce specific immune response, form antibodies and sensitized lymphocytes, but also react with them.
It is usually a protein, but polysaccharides and nucleic acids can also be used as antigens
Immunization planning vaccine refers to the vaccine provided to citizens free of charge in accordance with the provisions of the government, including the vaccine determined by the national immunization plan, the vaccine added by the people's governments of provinces, autonomous regions and municipalities directly under the central government in the implementation of the national immunization plan, and the emergency vaccination or vaccination organized by the people's governments at or above the county level or their competent health departments
Vaccines used for mass vaccination
Non immunization planned vaccine refers to the vaccine that is voluntarily vaccinated by citizens at their own expense. Corresponding to the immunization planned vaccine, the cost of vaccination of non immunization planned vaccine shall be borne by the recipient or his guardian
Class 1 prophylactic organisms refer to vaccines that are not marketed at home or abroad in accordance with the measures for the administration of drug registration (effective from July 1, 2020)
CDC refers to the center for Disease Control and prevention, a public welfare institution that implements national disease control and prevention and public health technology management and services
Culture medium refers to artificially prepared nutrients for the growth and maintenance of microorganisms and animal tissues
Combined vaccine refers to the vaccine that can prevent a variety of diseases by injecting the antigen components of two or more pathogenic organisms together
Polysaccharide vaccine refers to the vaccine made by purifying specific polysaccharide
Conjugate vaccine refers to the polysaccharide protein conjugate vaccine prepared by covalently binding polysaccharide to protein carrier by chemical method
Mcv2 refers to group A and group C meningococcal polysaccharide conjugate vaccine (CRM197 vector)
MCV4 refers to acyw135 meningococcal polysaccharide conjugate vaccine (CRM197 vector)
Ad5 EBOV refers to recombinant Ebola virus disease vaccine (adenovirus vector)
Pcv13i refers to 13 valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector)
PBPV refers to recombinant pneumococcal protein vaccine
DPT refers to whooping cough, diphtheria and tetanus
DTCP refers to adsorbed acellular pertussis, diphtheria and tetanus component vaccines
Haemophilus influenzae is a kind of non hemolytic bacteria, which usually exists in human nasopharynx. It is often a secondary infection of influenza. It is a pathogenic bacterium of meningitis in children
DTCP Hib refers to the combined vaccine of DPT and Haemophilus influenzae type B
Ad5-nCoV refers to recombinant New Coronavirus vaccine (type 5 adenovirus vector).
Adenovirus refers to a linear double stranded DNA envelope free virus, which has the ability to infect both mitotic and non mitotic cells, and has epithelial tropism. It is a common gene manipulation tool
Exogenous DNA refers to the DNA sequence introduced into target cells through genetic engineering technology or virus infection
Inactivated vaccine refers to the vaccine made by selecting virus or bacteria with strong immunogenicity and inactivating with inactivating agent
MRNA vaccine refers to a vaccine that is based on the mRNA structure corresponding to pathogen antigen protein and delivered to human cells through different delivery methods. After translation, it can stimulate cells to produce antigen protein and trigger specific immune response
CRM197 refers to diphtheria toxin non-toxic mutant
Hid refers to lipoprotein D on the surface of Haemophilus influenzae
Hin47 refers to the heat shock protein expressed by Haemophilus influenzae under environmental pressure
GMP refers to the abbreviation of good manufacturing practice, which is the standard of drug production quality management
NDA refers to the abbreviation of new drug application and the application for new drug marketing license
Preclinical research refers to the synthesis process, extraction method, physical and chemical properties and purity, dosage form selection, prescription screening, preparation process, test method, quality index, stability, pharmacology and toxicology of drugs
Clinical trial refers to the systematic study of drugs in human body (patients or healthy volunteers) to confirm or reveal the effects and adverse reactions of test drugs and / or the absorption, distribution, metabolism and excretion of test drugs, with the purpose of determining the effectiveness and safety of test drugs
Bioengineering of the Academy of Military Sciences refers to the Institute of bioengineering, Academy of military medicine, Academy of Military Sciences of the people's Liberation Army
Auscon refers to auscon biopharmaceutical (Nantong) Co., Ltd
Cdmo refers to contract development manufacturer in English
